Black checkmark with a sparkle and a curved line underneath on a white background.
Company

Nuo Therapeutics, Inc.

Ticker
AURX
Sector
Industry
Report date
November 14, 2026
Valye AI Score

94

Very high visibility
Recent developments
Recent developments summary

Recent news coverage includes general market and healthcare industry topics but no direct updates on Nuo Therapeutics' operations or financials.

Recent developments:
  • There are no recent company-specific news developments reported in the primary business news sources for Nuo Therapeutics as of November 2026.
  • Recent news items cover broader market themes such as tariffs, AI stocks, and other healthcare companies but do not mention Nuo Therapeutics directly.[N1][N2][N3][N4][N5][N6][N7][N8]
Overview

Nuo Therapeutics, Inc. develops and markets the Aurix System, a point-of-care medical device that processes a patient's own blood to produce platelet rich plasma (PRP) gel for treating chronic wounds such as diabetic foot ulcers, leg ulcers, and pressure ulcers. The Aurix System is FDA-cleared and reimbursed by Medicare following a National Coverage Determination issued in 2021. The company operates primarily in the U.S. advanced wound care market, estimated at $10.8 billion globally in 2021. Nuo Therapeutics has a distribution agreement with Smith+Nephew for a private label Aurix product in the U.S. and continues to market its own branded product. The company experienced a supply interruption in 2026 for a key reagent but is pursuing alternative sources. Financially, the company reported a net loss for the nine months ended September 30, 2026, with limited recent revenue disclosures.

Executive summary

Nuo Therapeutics, Inc. is a commercial-stage medical device company focused on chronic wound care with its FDA-cleared Aurix System that produces autologous platelet rich plasma for wound management. The company restarted operations in 2021 following a favorable Medicare coverage decision and has a distribution agreement with Smith+Nephew. Revenues increased from $1.4 million in 2024 to $3.1 million in 2025. Financial figures (if any) are summarized from the latest available SEC filings and are provided for informational purposes only — not financial advice.

Scenarios for AURX

Bull case model:

The Aurix System's FDA clearance and Medicare coverage provide a foundation for commercial growth in the chronic wound care market. Increasing physician awareness and expanding sales agent networks could broaden adoption. The distribution agreement with Smith+Nephew offers a stable revenue stream through private label sales. Clinical studies support Aurix's efficacy, potentially differentiating it from competitors. The company's efforts to secure alternative reagent supplies may mitigate supply risks and support uninterrupted product availability.

Bear case model:

Nuo Therapeutics faces risks from supply interruptions of critical reagents, as evidenced by the 2026 thrombin supply disruption, which could impair product availability and commercialization. The company's current financials show net losses and limited revenue scale. Market adoption depends on physician acceptance and reimbursement administration by local Medicare contractors, which may vary. Competition in the advanced wound care market is significant, and regulatory compliance remains complex. The company's reliance on a small commercial team and limited operational scale may constrain growth.

Moat:

Nuo Therapeutics' moat is based on its FDA-cleared Aurix System, which leverages autologous platelet rich plasma technology with documented clinical efficacy in chronic wound care. The company benefits from Medicare reimbursement coverage, including a National Coverage Determination, which supports economic viability. Its exclusive U.S. distribution agreement with Smith+Nephew for a private label product adds commercial reach. Intellectual property protections include trademarks, trade secrets, and contractual safeguards. However, the company faces supply chain risks for key reagents and operates in a competitive advanced wound care market.

Risks overview
Risks summary
Supply chain interruptions for key reagents and financial constraints pose significant risks to Nuo Therapeutics' commercialization and operational stability.
Risks details:

• Supply Chain Risk: The company experienced a supply interruption in 2026 for the bovine thrombin reagent supplied by Pfizer, causing a temporary out-of-stock situation. Alternative supplies and regulatory relief efforts are ongoing but not guaranteed.
• Financial Performance: Nuo Therapeutics reported net losses and limited revenue scale as of the latest filings, with a current ratio below 1 indicating potential liquidity constraints.
• Regulatory and Reimbursement Risk: The company's commercial viability depends on Medicare coverage and reimbursement administration, which may vary by region and over time. Compliance with FDA and other regulatory requirements is ongoing and complex.
• Market Adoption: Growth depends on increasing physician awareness and acceptance of Aurix therapy in a competitive advanced wound care market. The small commercial team may limit rapid expansion.

FINAL FORECAST FOR AURX

Final take one line
Nuo Therapeutics operates with high visibility into its FDA-cleared Aurix System for chronic wound care, supported by Medicare coverage and a key distribution agreement, but faces supply chain and financial risks.
Final take 12 to 24 month view

Business trends: Increasing commercial adoption of Aurix supported by Medicare reimbursement and expanding distributor relationships.
Execution milestones: Securing alternative reagent supplies, expanding sales agent network, and maintaining regulatory compliance.
Key risks: Supply interruptions of critical reagents, financial losses, reimbursement variability, and competitive market dynamics.

Valye AI Visibility Research Score

Very high visibility

Visibility score reflects the breadth and consistency of available disclosure across SEC filings, recent public reporting, and baseline business context (research-only; not investment advice).

94
LLM visibility overview
LLM Visibility known facts
  • Nuo Therapeutics, Inc. is a Delaware corporation originally organized in 1998 and renamed in 2014 from Cytomedix, Inc.
  • The company is a commercial-stage medical device company focused on developing and marketing products for chronic wound care primarily in the U.S.
  • Its principal commercial product is the Aurix System, an FDA-cleared device (since 2007) that processes peripheral blood to produce autologous platelet rich plasma (PRP) for wound management.
  • Aurix is cleared for marketing under FDA Section 510(k) and is one of three platelet-derived products cleared for chronic wound care use, including diabetic ulcers, leg ulcers, pressure ulcers, and other exuding wounds.
  • The advanced wound care market is estimated at approximately $10.8 billion globally in 2021, with the North American market about $4.15 billion in 2020.
  • Aurix produces a biologically active hematogel from the patient's own blood platelets and plasma, which releases growth factors and signaling molecules to promote wound healing.
  • The company experienced a period of ceased operations in 2019 awaiting Medicare coverage reconsideration but restarted business activities in October 2021 after CMS issued a favorable National Coverage Determination (NCD) in April 2021 for autologous PRP products.
  • CMS reimbursement rates for Aurix in 2026 are approximately $2,108 per treatment in hospital outpatient departments (POS 22) and $1,064 per treatment in physician offices (POS 11).
  • Nuo Therapeutics has a Distribution Agreement with Smith+Nephew, granting exclusive U.S. distribution rights for a private label Aurix product, with minimum annual purchase commitments and upfront fees totaling $1.5 million plus potential additional fees.
  • The company markets and sells its own Aurix branded product alongside the private label product distributed by Smith+Nephew.
  • Commercial revenues increased from approximately $1.4 million in 2024 to approximately $3.1 million in 2025, with total 2025 revenues around $3.3 million including distribution fees.
  • As of December 31, 2025, the company had contractual relationships with over 200 third-party sales representatives.
  • Nuo Therapeutics relies on trademarks, trade secrets, copyrights, confidentiality agreements, and contractual provisions to protect its intellectual property.
  • The company is subject to extensive regulation by U.S. and international authorities for its medical devices, including FDA clearance and ongoing compliance.
  • Aurix therapy has documented clinical efficacy in peer-reviewed studies, showing improved healing rates and times for diabetic foot ulcers and other chronic wounds.
  • The company experienced a supply interruption in 2026 for the bovine thrombin reagent (Thrombin-JMI) supplied by Pfizer, causing a temporary out-of-stock situation for about two weeks in August 2026.
  • Nuo Therapeutics is pursuing alternative thrombin supplies and regulatory relief to mitigate supply risks, including human recombinant thrombin and international sources.
  • Financial snapshot as of September 30, 2026: cash and equivalents of $80,941; current assets of $1,984,064; current liabilities of $2,454,508; resulting in a current ratio of 0.81 and a cash ratio of 0.03.
  • Net income for the nine months ended September 30, 2026 was a loss of $424,928; basic EPS was -$0.01 for the same period.
  • Revenue reported was $721,045 for the fiscal year ended December 31, 2017, with no more recent revenue figures disclosed in SEC filings.
  • The company has a small commercial team of four senior employees leveraging relationships to expand sales agent arrangements and distributor networks primarily in the U.S.
Sources
Sources - Context summary

Generated 2026-11-14

Sources - Earning calls
Sources - Other context
Sources - SEC Filings
  • S1 | 2026-03-30 | 10-K
  • S2 | 2026-11-13 | 10-Q
Sources - News headlines
  • N1 | 2026-11-14 | www.nasdaq.com | Soybeans Popping Higher on Friday Following Export Announcements | https://www.nasdaq.com/articles/soybeans-popping-higher-friday-following-export-announcements
  • N2 | 2026-11-14 | www.nasdaq.com | Soybeans Post Friday Gains Following Export Announcements | https://www.nasdaq.com/articles/soybeans-post-friday-gains-following-export-announcements
  • N3 | 2026-11-14 | www.nasdaq.com | Tariffs Pushed Prices Up. Why Retail and Industrial Investors Shouldn't Expect a Quick Reversal | https://www.nasdaq.com/articles/tariffs-pushed-prices-why-retail-and-industrial-investors-shouldnt-expect-quick-reversal
  • N4 | 2026-11-14 | www.nasdaq.com | Arrive AI: 3 Key Takeaways for Long-Term Investors | https://www.nasdaq.com/articles/arrive-ai-3-key-takeaways-long-term-investors
  • N5 | 2026-11-14 | www.nasdaq.com | Novo Nordisk Secures EU Approval For FREHEMGO In Haemophilia A | https://www.nasdaq.com/articles/novo-nordisk-secures-eu-approval-frehemgo-haemophilia
  • N6 | 2026-11-14 | www.nasdaq.com | COSCIENS Biopharma Inc. Q3 Loss Widens | https://www.nasdaq.com/articles/cosciens-biopharma-inc-q3-loss-widens
  • N7 | 2026-11-14 | www.nasdaq.com | Alphamin Resources Corp. Profit Climbs In Q3 | https://www.nasdaq.com/articles/alphamin-resources-corp-profit-climbs-q3
  • N8 | 2026-11-14 | www.nasdaq.com | Bragg Gaming Group Inc. Q3 Loss Rises | https://www.nasdaq.com/articles/bragg-gaming-group-inc-q3-loss-rises
Important legal disclaimer

This material is for informational purposes only and does not constitute investment, financial, legal or tax advice, or an offer or solicitation to buy or sell any security. The Valye AI Score is a model-based estimate derived from public information and is subject to change without notice. No representation or warranty, express or implied, is made as to the accuracy, completeness or fairness of the information herein. Past performance is not indicative of future results. Investors should conduct their own research and consult a qualified financial adviser before making any investment decisions.

Blue logo with a stylized checkmark and star above the blue text 'VALYE' on a black background.

Generated by Valye SEC Pipeline Engine